Results 31 to 40 of about 5,485 (197)

Consensus on the Treatment of Adrenocortical Carcinoma with Mitotane(2021)

Xiehe Yixue Zazhi, 2021
Adrenocortical carcinoma (ACC) is a rare malignant tumor that occurs in the adrenal cortex, and surgery is the first choice for treating ACC. Medical therapy and radiotherapy are adjuvant treatments for patients with unresectable metastasized tumors or ...
Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital
doaj   +1 more source

Stimulation of Erythrocyte Cell Membrane Scrambling by Mitotane

Cellular Physiology and Biochemistry, 2014
Background: Mitotane (1,1-dichloro-2-[o-chlorophenyl]-2-[p-chlorophenyl]ethane), a cytostatic drug used for the treatment of adrenocortical carcinomas, is effective by triggering tumor cell apoptosis. In analogy to apoptosis of nucleated cells, eryptosis
Janin Jacobi, Elisabeth Lang, Rosi Bissinger, Leonie Frauenfeld, Paola Modicano, Caterina Faggio, Majed Abed, Florian Lang   +7 more
doaj   +1 more source

Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study [PDF]

, 2017
Background: Metastatic Adrenocortical Carcinoma (ACC) is a rare malignancy with a poor 5-year-survival rate (
Christine Spitzweg, Christoph-Thomas Germer, Felix Megerle, Johannes Baur, Marcus Quinkler, Martin Fassnacht, Matthias Kroiss, on behalf of the German Adrenocortical Carcinoma Study Group, Peter Nawroth, Timo Deutschbein, Tjark-Ole Büntemeyer, Ulrich Steger   +11 more
core   +1 more source

Long-term partial response in a patient with liver metastasis of primary adrenocortical carcinoma with adjuvant mitotane plus transcatheter arterial chemoembolization and microwave ablation: a case report

Frontiers in Oncology, 2023
Adrenocortical carcinoma (ACC) is a rare, heterogeneous, and aggressive malignancy with a generally poor prognosis. Surgical resection is the optimal treatment plan.
Jianhua Deng, Lihui Wei, Qihuang Fan, Zoey Wu, Zhigang Ji   +4 more
doaj   +1 more source

Medical treatment of Cushing's syndrome: Adrenal-blocking drugs and ketaconazole [PDF]

, 2010
Cushing's syndrome is associated with serious morbidity and increased mortality. Irrespective of its cause, i.e. a pituitary adenoma, ectopic ACTH production or an adrenal neoplasia, Cushing's syndrome is primarily treated surgically.
Feelders, R.A. (Richard), Herder, W.W. (Wouter) de, Hofland, L.J. (Leo)   +2 more
core   +4 more sources

Influence of Plasma Triglyceride Levels on Mitotane Therapeutic Drug Monitoring in Adrenocortical Carcinoma: Translational Implications from a Case Report

International Journal of Translational Medicine
Background: Mitotane is the cornerstone adjuvant and palliative treatment for adrenocortical carcinoma (ACC), requiring strict therapeutic drug monitoring (TDM) due to its narrow therapeutic window and high inter- and intra-individual pharmacokinetic ...
Sonia Fernández-Cañabate, Asunción Díaz-Serrano, Álvaro Corral-Alaejos   +2 more
doaj   +1 more source

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options

Endocrine Oncology, 2023
Adrenocortical carcinoma (ACC) is a rare cancer with high recurrence rates and heterogeneous clinical behavior. The role of adjuvant therapy remains unclear because of the challenges in collecting high-quality data for a rare cancer.
Ruaa Al-Ward, Celeste Zsembery, Mouhammed Amir Habra   +2 more
doaj   +1 more source

Diabetes mellitus secondary to Cushing's disease [PDF]

, 2018
Associated with important comorbidities that significantly reduce patients’ overall wellbeing and life expectancy, Cushing’s disease (CD) is the most common cause of endogenous hypercortisolism.
Barbot, Mattia, Ceccato, Filippo, Scaroni, Carla   +2 more
core   +2 more sources

Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients [PDF]

, 2015
Background: Cushing's syndrome (CS) is a severe condition with excess mortality and significant morbidity necessitating control of hypercortisolemia.
Aylwin, S., Ball, S., Boelaert, K., Cheer, K., Chortis, V., Cuthbertson, D.J., Daniel, E., Daousi, C., Davis, J., Drake, W., Grossman, A., Gunganah, K., Gurnell, M., Hill, N., Huguet, I., Karavitaki, N., Kearney, T., Lansdown, A.J., Meeran, K., Minder, A-EH., Mohit, K., Munir, A., Mustafa, O., Newell-Price, J., Powlson, A.S., Rajeev, S.P., Rees, A., Trainer, P.J.   +27 more
core   +2 more sources

The impact of mitotane therapy on serum-free proteins in patients with adrenocortical carcinoma

Endocrine Connections
Introduction: Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex. Whilst surgery is the preferred treatment, adjunctive therapy with mitotane may be offered post-surgically to minimise the risk of recurrence or, in the absence of ...
Magdalena Lech, Ruvini Ranasinghe, Royce P Vincent, David R Taylor, Lea Ghataore, James Luxton, Fannie Lajeunesse-Trempe, Pia Roser, Eftychia E Drakou, Ling Ling Chuah, Ashley B Grossman, Simon J B Aylwin, Georgios K Dimitriadis   +12 more
doaj   +1 more source